The landscape of genetic testing for prostate cancer is rapidly evolving. There is increasing evidence that individuals with germline mutations in DNA-repair genes are more responsive to targeted therapies. Due to potential implications for treatment, these genes should be taken into consideration when determining the scope of genetic testing.
|Original language||English (US)|
|Number of pages||3|
|Journal||The Canadian journal of urology|
|State||Published - Oct 1 2019|
ASJC Scopus subject areas